Sanofi is one of the world’s leading pharmaceutical companies.
Sanofi reported full year 2025 revenues of $51.6 billion — a 6.2% increase — anchored by Dupixent’s extraordinary commercial performance of $18.5 billion, making it the world’s best-selling non-oncology biologic. Sanofi’s strategic transformation over the past five years has been profound — divesting Sanofi Consumer Healthcare into Opella, exiting multiple legacy businesses, and concentrating capital on Dupixent expansion, the type 2 inflammation pipeline, vaccines through Sanofi Pasteur, and rare blood disorders through Genzyme.
This report provides comprehensive strategic intelligence on Sanofi — covering strategic directions, financial performance, SWOT analysis, technological know-how, latest products and services, M&A, marketing tactics, and organization and management.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and key platforms
• Latest products, programs, and innovation pipeline
• M&A activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Sanofi — Key Financial Metrics 2023-2025
Table 2. Sanofi — Revenue by Therapeutic Area 2023-2025
Table 3. Sanofi — Revenue by Geography 2023-2025
Table 4. Sanofi — R&D Investment 2023-2025
Table 5. Sanofi — SWOT Analysis
Table 6. Sanofi — Key Technology Platforms
Table 7. Sanofi — Top Products by Revenue 2025
Table 8. Sanofi — Late-Stage Pipeline 2025
Table 9. Sanofi — M&A Activity 2023-2025
Table 10. Sanofi — Key Management
Table 11. Sanofi — Strategic Priorities 2025-2030
